Navigation Links
Pervasis Receives FDA Fast Track Status for Vascugel® to Prevent Arteriovenous Access Failure in Patients Undergoing Hemodialysis
Date:2/8/2011

all arteriovenous (AV) grafts require re-intervention after one year.(1,2) AV access failure is the most common reason for hospitalization among hemodialysis patients and can lead to anemia, infection, weight loss, jaundice, prolonged bleeding, and other serious complications.(3)

Vascugel – Combating Inflammation and Promoting HealingPervasis' novel approach to cell therapy uses adult-differentiated allogeneic endothelial cells (donor endothelial cells with a highly targeted biologic function) embedded in a patented polymer matrix to enhance the body's natural healing response. The endothelium is the thin layer of cells that lines the interior surface of blood vessels in the body. Endothelial cells are critical to tissue repair and health, and have a well-understood role in regulating many of the body's healing processes, including those associated with vascular repair.

Vascugel, which utilizes Pervasis' patented endothelial cell-based platform, is placed on the outside of the blood vessel at the AV access site during the surgical intervention to create the AV access point. The endothelial formulations in Vascugel secrete several factors that combat inflammation and promote proper vascular healing, reducing thrombosis (or clotting) and the formation of intimal hyperplasia, or a thickening of the blood vessel wall in response to injury. After approximately four to eight weeks, Vascugel is safely resorbed by the body.

The company's other areas of clinical investigation include improving outcomes in patients with peripheral artery disease (PAD) following surgical procedures such as percutaneous transluminal angioplasties (PTAs) with stenting, the failures of which result in serious complications and a significant increase in medical costs. Last month, Pervasis announced it has also embarked on an oncology development program using its proprietary endothelial cell-based platform to prevent solid tumor growth, cancer recurrence and metasta
'/>"/>

SOURCE Pervasis Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pervasis to Present Interim Data from Phase 1/2 Clinical Study of Novel Cell Therapy Targeting Peripheral Artery Disease at International Conference on Cell Therapy for Cardiovascular Diseases
2. Pervasis Therapeutics to Develop Novel Cell-Based Approach to Target Tumor Environment, Prevent Cancer Recurrence
3. Pervasis Therapeutics Awarded Four Grants Under the Qualifying Therapeutic Discovery Project
4. Pervasis Therapeutics Receives FDA Clearance for Pivotal Phase 3 Trial of Vascugel(R)
5. Generex Oncology Receives New Patent for AE37 Immunotherapeutic Cancer Vaccine
6. China Medicine Corporation Receives Manufacturing License for rADTZ
7. Johnson & Johnson Receives Approval from European Commission
8. Mylan Receives Approval for First-to-File Generic Sular® Extended-Release Tablets
9. Boca Pharmacal Receives FDA Approval for Hydrocodone Bitartrate and Acetaminophen Tablets
10. China Sky One Medical Receives Medical Industry Awards
11. Lakewood-Amedex Inc. Receives Notice of Allowance on Three US Patent Applications Relating to Treatment of Hemolytic Uremic Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... Calif. , April 30, 2015  Accuray ... it has signed an agreement with MIM Software ... the TomoTherapy ® and CyberKnife ® product ... Accuray and MIM technology. This is Accuray,s second ... the development of the first iPad-based treatment plan ...
(Date:4/30/2015)... , April 30, 2015  Thoratec Corporation (NASDAQ: ... therapies to save, support and restore failing hearts, said ... Merrill Lynch 2015 Healthcare Conference on Thursday, May 14. ... Chief Executive Officer, will provide an update on the ... p.m., Eastern Daylight Time). The presentation will ...
(Date:4/30/2015)... 2015  DURECT Corporation (Nasdaq: DRRX ) announced ...  Total revenues were $4.8 million and net loss was ... 2015 as compared to total revenues of $6.3 million ... months ended March 31, 2014.At March 31, 2015, we ... cash and investments of $34.9 million at December 31, ...
Breaking Medicine Technology:Accuray Signs Agreement with MIM Software Inc. to Develop Adaptive Therapy Software 2Accuray Signs Agreement with MIM Software Inc. to Develop Adaptive Therapy Software 3Thoratec Presentation At Bank Of America Merrill Lynch Healthcare Conference To Be Webcast 2DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 2DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 3DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 4DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 5DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 6DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 7DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 8DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 9
... /PRNewswire/ -- Argus Health Systems, Inc., a ... with Walmart to provide expanded network services. This Preferred ... provide the lowest prescription benefit cost to Argus customers. ... customers a more cost-effective pharmacy network alternative. Access to ...
... Sept. 22, 2011 Watson Pharmaceuticals, Inc. (NYSE: ... and Sandoz Inc. have filed suit against Amphastar Pharmaceuticals, ... United States District Court for the District of Massachusetts. ... which Watson has the exclusive right to distribute in ...
Cached Medicine Technology:Argus Announces Retail Network Relationship 2Watson Confirms Amphastar Patent Lawsuit 2Watson Confirms Amphastar Patent Lawsuit 3
(Date:5/1/2015)... Caicos Islands, BWI (PRWEB) May 02, 2015 ... website! It is http://www.thevenetiangracebay.com , and it ... it incorporates the stunning white and attractive turquoise hues ... study of Google, sixty seven percent of leisure travelers ... study showed that smartphones were used in the planning ...
(Date:5/1/2015)... 2015 Jusuru International has been awarded ... repositioning of its flagship nutritional supplement, Liquid BioCell™ Life, ... new name, new logo, new packaging, new products, and ... designed to identify and promote programs that serve as ... “DSA congratulates Jusuru International for their outstanding accomplishments and ...
(Date:5/1/2015)... The Workgroup for Electronic Data Interchange ... use of health IT to create efficiencies in healthcare ... the United States Government Accountability Office (GAO) for a ... Medicare. The report, “ Potential Uses of Electronically Readable ... the public on Apr. 24, 2015 and examines the ...
(Date:5/1/2015)... 01, 2015 It’s raining bills on Capitol ... proposals to expand federal support for telemedicine. , ... has been working with Congress,” said Jonathan Linkous, CEO of ... the nation is poised to embrace the use of telecommunications ... step in fulfilling ATA’s mission to improve quality, access, equity ...
(Date:5/1/2015)... KY (PRWEB) May 01, 2015 Ernst ... CEO, Dr. Joshua Rosenthal, Co-Founder & CSO, and Burak ... finalists for the EY Entrepreneur Of The Year® ... Ernst & Young is a global leader in ... to be one of the top audit companies ...
Breaking Medicine News(10 mins):Health News:Turks and Caicos Resort, The Venetian on Grace Bay, Launches New Web Presence 2Health News:Jusuru International Receives 2015 DSA Ethos Award 2Health News:Jusuru International Receives 2015 DSA Ethos Award 3Health News:Jusuru International Receives 2015 DSA Ethos Award 4Health News:Jusuru International Receives 2015 DSA Ethos Award 5Health News:WEDI Contributes to Newly Released U.S. Government Accountability Office (GAO) Study on Potential Use of Electronically Readable Medicare Cards 2Health News:WEDI Contributes to Newly Released U.S. Government Accountability Office (GAO) Study on Potential Use of Electronically Readable Medicare Cards 3Health News:ATA: Congress Floods the Halls with Telemedicine Proposals 2Health News:RowdMap, Inc. Named as a Ernst & Young Entrepreneur Of The Year® 2015 Award Finalist 2
... research shows , , FRIDAY, June 13 (HealthDay News) -- ... the morning may help ease some stresses you might ... rats inhaled the aroma of roasted coffee beans, a ... proteins with healthful antioxidant activity, the researchers reported. ...
... Md., June 13 EntreMed, Inc.,(Nasdaq: ... for the treatment of cancer and inflammatory ... and Chief Executive Officer,will present a Company ... Industry Organization 2008 Annual International Convention,being held ...
... blames traffic-related pollution for increasing the risk of allergy and ... more, the closer children live to roads, the higher their ... are likely to be exposed not only to a higher ... more freshly emitted aerosols which may be more toxic," wrote ...
... the most commonly ... June 13 Roche announced today that,its new test ... allowing it to be sold for clinical use in ... approach to help ensure,reliability of test results even when ...
... Arthritis is the Leading Cause of Work Disability ... data announced today,showed that treating patients with early, ... methotrexate (MTX) resulted in an,indirect cost savings of ... the time of the study) per patient per ...
... Lower Manhattan, the terrorist attacks of September 11, 2001, ... the Health Department,s World Trade Center Health Registry, show ... posttraumatic stress disorder (PTSD) two to three years after ... developed PTSD at three times the usual rate in ...
Cached Medicine News:Health News:Coffee Beans May Be Newest Stress-Buster 2Health News:Coffee Beans May Be Newest Stress-Buster 3Health News:EntreMed to Present at the BIO 2008 Annual International Convention 2Health News:Road pollution blamed for higher allergy risk in kids 2Health News:New Roche Chlamydia Test Approved for Use in European Union 2Health News:New Roche Chlamydia Test Approved for Use in European Union 3Health News:HUMIRA(R) (adalimumab) Data Show That Treating Early Rheumatoid Arthritis With Combination Treatment Resulted in Cost Savings From Improved Work Productivity 2Health News:HUMIRA(R) (adalimumab) Data Show That Treating Early Rheumatoid Arthritis With Combination Treatment Resulted in Cost Savings From Improved Work Productivity 3Health News:HUMIRA(R) (adalimumab) Data Show That Treating Early Rheumatoid Arthritis With Combination Treatment Resulted in Cost Savings From Improved Work Productivity 4Health News:HUMIRA(R) (adalimumab) Data Show That Treating Early Rheumatoid Arthritis With Combination Treatment Resulted in Cost Savings From Improved Work Productivity 5Health News:HUMIRA(R) (adalimumab) Data Show That Treating Early Rheumatoid Arthritis With Combination Treatment Resulted in Cost Savings From Improved Work Productivity 6Health News:HUMIRA(R) (adalimumab) Data Show That Treating Early Rheumatoid Arthritis With Combination Treatment Resulted in Cost Savings From Improved Work Productivity 7Health News:1 in 8 Lower Manhattan residents had signs of PTSD 2 to 3 years after 9/11 2
This aron protects at 0.5 mm Pb equivalency and is 20% lighter than our Standard Back-Aid Apron - yet it contains no lead products that can be harmful to the environment!...
Crisscross shoulder design facilitates better posture and distributes weight to back and hips for greater comfort. Shoulder pads soften shoulder contact with apron for additional comfort....
Use this workhorse apron where 360 of protection from direct and scatter radiation is required....
... Our popular Back-Aid Apron now ... Universal Back-Saver Belt that has ... more weight off your shoulders! ... strap redistribute weight from the ...
Medicine Products: